We demonstrate that VMP1 is overexpressed in gliomas and could confer survival advantages through enhanced angiogenesis, and that bevacizumab (BEV), a VEGFA‐targeted therapy, effectively suppresses VMP1‐driven tumor growth. Here, VMP1 is linked to neoplasm.